Copyright Reports & Markets. All rights reserved.

Global Befotertinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Befotertinib Mesylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 50 mg/tablet
    • 1.3.3 75 mg/tablet
  • 1.4 Market Analysis by Sales Channels
    • 1.4.1 Overview: Global Befotertinib Mesylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Retail
    • 1.4.4 Online
  • 1.5 Market Analysis by Combined Medication
    • 1.5.1 Overview: Global Befotertinib Mesylate Consumption Value by Combined Medication: 2021 Versus 2025 Versus 2032
    • 1.5.2 Befotinib + Bevacizumab
    • 1.5.3 Befotinib + Trametinib
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Befotertinib Mesylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Non-small Cell Lung Cancer (NSCLC) Treatment
    • 1.6.3 Post-resistance Treatment
    • 1.6.4 Brain Metastases
    • 1.6.5 Others
  • 1.7 Global Befotertinib Mesylate Market Size & Forecast
    • 1.7.1 Global Befotertinib Mesylate Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Befotertinib Mesylate Sales Quantity (2021-2032)
    • 1.7.3 Global Befotertinib Mesylate Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Betta Pharmaceuticals
    • 2.1.1 Betta Pharmaceuticals Details
    • 2.1.2 Betta Pharmaceuticals Major Business
    • 2.1.3 Betta Pharmaceuticals Befotertinib Mesylate Product and Services
    • 2.1.4 Betta Pharmaceuticals Befotertinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Betta Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Befotertinib Mesylate by Manufacturer

  • 3.1 Global Befotertinib Mesylate Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Befotertinib Mesylate Revenue by Manufacturer (2021-2026)
  • 3.3 Global Befotertinib Mesylate Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Befotertinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Befotertinib Mesylate Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Befotertinib Mesylate Manufacturer Market Share in 2025
  • 3.5 Befotertinib Mesylate Market: Overall Company Footprint Analysis
    • 3.5.1 Befotertinib Mesylate Market: Region Footprint
    • 3.5.2 Befotertinib Mesylate Market: Company Product Type Footprint
    • 3.5.3 Befotertinib Mesylate Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Befotertinib Mesylate Market Size by Region
    • 4.1.1 Global Befotertinib Mesylate Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Befotertinib Mesylate Consumption Value by Region (2021-2032)
    • 4.1.3 Global Befotertinib Mesylate Average Price by Region (2021-2032)
  • 4.2 North America Befotertinib Mesylate Consumption Value (2021-2032)
  • 4.3 Europe Befotertinib Mesylate Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Befotertinib Mesylate Consumption Value (2021-2032)
  • 4.5 South America Befotertinib Mesylate Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Befotertinib Mesylate Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 5.2 Global Befotertinib Mesylate Consumption Value by Type (2021-2032)
  • 5.3 Global Befotertinib Mesylate Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 6.2 Global Befotertinib Mesylate Consumption Value by Application (2021-2032)
  • 6.3 Global Befotertinib Mesylate Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 7.2 North America Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 7.3 North America Befotertinib Mesylate Market Size by Country
    • 7.3.1 North America Befotertinib Mesylate Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Befotertinib Mesylate Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 8.2 Europe Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 8.3 Europe Befotertinib Mesylate Market Size by Country
    • 8.3.1 Europe Befotertinib Mesylate Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Befotertinib Mesylate Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Befotertinib Mesylate Market Size by Region
    • 9.3.1 Asia-Pacific Befotertinib Mesylate Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Befotertinib Mesylate Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 10.2 South America Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 10.3 South America Befotertinib Mesylate Market Size by Country
    • 10.3.1 South America Befotertinib Mesylate Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Befotertinib Mesylate Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Befotertinib Mesylate Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Befotertinib Mesylate Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Befotertinib Mesylate Market Size by Country
    • 11.3.1 Middle East & Africa Befotertinib Mesylate Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Befotertinib Mesylate Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Befotertinib Mesylate Market Drivers
  • 12.2 Befotertinib Mesylate Market Restraints
  • 12.3 Befotertinib Mesylate Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Befotertinib Mesylate and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Befotertinib Mesylate
  • 13.3 Befotertinib Mesylate Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Befotertinib Mesylate Typical Distributors
  • 14.3 Befotertinib Mesylate Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Befotertinib Mesylate market size was valued at US$ 412 million in 2025 and is forecast to a readjusted size of US$ 2289 million by 2032 with a CAGR of 24.4% during review period.
    Befotertinib mesylate is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which is mainly used for the treatment of non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations. By selectively inhibiting the activity of mutant EGFR, this drug blocks the signaling pathways responsible for the proliferation and growth of tumor cells, and also exerts a certain inhibitory effect on the T790M drug-resistant mutation. Compared with early-generation EGFR inhibitors, befotertinib mesylate delivers enhanced efficacy while posing relatively little impact on normal cells, with favorable safety and tolerability profiles. Common adverse reactions include rash, diarrhea, abnormal liver function and other symptoms. Therefore, relevant indicators need to be monitored regularly during medication to ensure safe and effective drug use.
    Befotertinib mesylate is a third-generation EGFR tyrosine kinase inhibitor (TKI) targeting non-small cell lung cancer (NSCLC) with EGFR mutations, particularly designed for patients with the T790M resistance mutation. Against the backdrop of continuous advancements in precision medicine, it benefits from a stable clinical demand. With China’s large lung cancer patient population and the increasing penetration of genetic testing, the EGFR-targeted therapy market continues to expand, providing strong commercial opportunities for this drug.
    In terms of the competitive landscape, imported originator drugs represented by Osimertinib still dominate the market. However, befotertinib mesylate, leveraging its domestic R&D advantages, relatively controlled pricing, and potential inclusion in medical insurance, is well positioned to gain market share in lower-tier cities and among price-sensitive patient groups. Meanwhile, national volume-based procurement and healthcare cost-control policies exert downward pressure on overall pricing, while also pushing companies to strengthen competitiveness through expanding indications, generating real-world evidence, and enhancing academic promotion.
    Overall, the market prospects of befotertinib mesylate depend on its clinical efficacy and safety profile, differentiated positioning, and pricing and channel strategies within the evolving policy environment.
    This report is a detailed and comprehensive analysis for global Befotertinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Befotertinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Befotertinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Befotertinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Befotertinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Befotertinib Mesylate
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Befotertinib Mesylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Betta Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Befotertinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    50 mg/tablet
    75 mg/tablet
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Combined Medication
    Befotinib + Bevacizumab
    Befotinib + Trametinib
    Market segment by Application
    Non-small Cell Lung Cancer (NSCLC) Treatment
    Post-resistance Treatment
    Brain Metastases
    Others
    Major players covered
    Betta Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Befotertinib Mesylate product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Befotertinib Mesylate, with price, sales quantity, revenue, and global market share of Befotertinib Mesylate from 2021 to 2026.
    Chapter 3, the Befotertinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Befotertinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Befotertinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Befotertinib Mesylate.
    Chapter 14 and 15, to describe Befotertinib Mesylate sales channel, distributors, customers, research findings and conclusion.

    Buy now